Angeliq

Atrophic Vaginitis, Low Testosterone, Hypogonadism + 27 more

Treatment

5 FDA approvals

20 Active Studies for Angeliq

What is Angeliq

Estradiol

The Generic name of this drug

Treatment Summary

Estradiol is a hormone that is naturally produced by females. It is used in hormone therapy to treat conditions caused by low estrogen levels, such as hot flashes and thinning of the vaginal walls. It can be taken orally in pill form, injected, inserted into a vaginal ring, applied to the skin through patches, sprays, gels, and creams, or taken as a pro-drug ester. A synthetic form of estradiol called ethinyl estradiol is commonly used in combination birth control pills, as it has higher bioavailability and is more resistant to metabolism.

Estraderm

is the brand name

Angeliq Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Estraderm

Estradiol

1986

373

Approved as Treatment by the FDA

Estradiol, also known as Estraderm, is approved by the FDA for 5 uses like Hormonal Contraception and Breast Cancer .

Hormonal Contraception

Used to treat Hormonal Contraception therapy in combination with Levonorgestrel

Breast Cancer

Birth Control

Used to treat Contraception in combination with Levonorgestrel

Palliative Treatment

Breast Cancer

Effectiveness

How Angeliq Affects Patients

Estradiol helps to reduce symptoms like hot flashes, vaginal dryness, and pain during sex. It also helps to increase bone density and can improve the levels of certain proteins in the liver. It can also reduce levels of FSH in the pituitary gland. However, estradiol can increase the risk of cardiovascular conditions such as DVT and stroke, and should be avoided in people at high risk. It can also cause a hyper-coagulable state and increases in angiotensin, which may lead to hypertension.

How Angeliq works in the body

Estrogen is a hormone found in many parts of the body, including the breasts, uterus, ovaries, skin, prostate, bones, fat, and brain. It's mainly produced in the ovaries before menopause, then mostly made by the adrenal glands afterward. Estrogen has two main types: estradiol, which is more potent and has powerful effects, and estrone, which is more common in postmenopausal women. Estrogen works by attaching to receptors in the body's cells and entering their nucleus. This causes the cell to produce proteins that express its effects. Estrogen increases pro-estrogenic effects

When to interrupt dosage

The measure of Angeliq is contingent upon the identified disorder, including Premature Menopause, Pharmaceutical Preparations and Postmenopause. The dosage also differs as per the technique of delivery specified in the table underneath.

Condition

Dosage

Administration

Hot flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Hormone Replacement Therapy

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

estradiol

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

female castration

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Postmenopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Prostate Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Breast

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Palliative Treatment

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Breast Cancer

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Hot Flashes

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Vasomotor System

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Pharmaceutical Preparations

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Amenorrhea

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Premature Menopause

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Atrophic

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Balanitis Xerotica Obliterans

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Therapeutic procedure

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Hypogonadism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Osteoporosis

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

hypoestrogenism

0.00052 mg/mg, , 0.005 mg/hour, 0.5 mg, 1.0 mg, 0.00025 mg/mg, 0.0005 mg/mg, 0.001 mg/mg, 2.0 mg, 0.0025 mg/hour, 0.0075 mg/hour, 0.01 mg/hour, 0.00375 mg/hour, 0.006 mg/hour, 1.53 mg, 0.0006 mg/mg, 10.0 mg/mL, 40.0 mg/mL, 20.0 mg/mL, 0.0014 mg/hour, 5.0 mg/mL, 0.097 mg/[USP'U], 0.146 mg/[USP'U], 0.194 mg/[USP'U], 4.4 mg, 0.01 mg/[USP'U], 0.01 mg, 10.0 mg, 12.5 mg, 15.0 mg, 18.0 mg, 20.0 mg, 22.0 mg, 25.0 mg, 6.0 mg, 5.0 mg, 0.06 %, 4.0 mg, 8.0 mg, 0.1 %, 3.28 mg, 4.33 mg, 8.66 mg, 6.56 mg, 0.025 mg, 0.00075 mg/mg, 0.51 mg, 0.62 mg, 0.0001 mg/mg, 0.0045 mg/hour, 0.0052 mg/mg, 1.5 mg, 1.8 mg, 2.5 mg/mL, 0.45 mg, 0.9 mg, 0.05 mg, 0.004 mg, 0.0025 mg/mg, 2.17 mg, 6.57 mg, 4.84 mg, 4.95 mg, 14.0 mg, 0.005 mg/mg, 0.0075 mg/mg, 50.0 mg, 0.00125 mg/mg, 0.00005 mg/mg

Topical, Gel, metered, , Gel, metered - Topical, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Tablet, Oral, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Gel, Gel - Topical, Patch - Transdermal, Patch, Spray, Spray - Transdermal, Gel - Transdermal, Injection - Intramuscular, Intramuscular, Vaginal, Ring, Spray, metered - Transdermal, Tablet, film coated - Vaginal, Spray, metered, Film, extended release, Film, extended release - Transdermal, Pellet, Pellet - Oral, Tablet - Vaginal, Oral; Transdermal, Insert, Insert - Vaginal, Cream - Vaginal, Cream, Injection, solution - Intramuscular, Gel, metered - Transdermal, Emulsion - Topical, Emulsion, Ring - Vaginal, Lotion - Topical, Capsule, Capsule - Oral, Pellet, implantable - Subcutaneous, Pellet, implantable, Capsule; Spray, metered - Oral; Transdermal, Cream - Transdermal, Capsule; Spray, metered

Warnings

Angeliq has eighteen contraindications, thus it should not be consumed when experiencing any of the conditions specified in the following table.

Angeliq Contraindications

Condition

Risk Level

Notes

Breast

Do Not Combine

Angioedema

Do Not Combine

Venous Thrombosis

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

Liver Dysfunction

Do Not Combine

Breast

Do Not Combine

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

Pulmonary Embolism

Do Not Combine

Angioedema

Do Not Combine

Deep Vein Thrombosis

Do Not Combine

Thromboembolism

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Pulmonary Embolism

Do Not Combine

Thromboembolism

Do Not Combine

Thrombophilia

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Estradiol may interact with Pulse Frequency

There are 20 known major drug interactions with Angeliq.

Common Angeliq Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Estradiol.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Estradiol.

Anastrozole

Major

The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estradiol.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Estradiol.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Estradiol.

Angeliq Toxicity & Overdose Risk

The most toxic amount of estradiol when taken orally for a period of 90 days was 0.003mg/kg/day for blood, female reproductive, and male reproductive, endocrine, and liver toxicity. The lowest toxic dose for ethinyl estradiol is 21 mg/kg/21D for women. The highest toxic dose is 960 mg/kg in rats. Taking too much estradiol may lead to symptoms such as nausea, vomiting, abdominal pain, breast tenderness, blood clots, and vaginal bleeding. If an overdose occurs, it is recommended to stop taking estradiol and provide supportive care.

Angeliq Novel Uses: Which Conditions Have a Clinical Trial Featuring Angeliq?

Currently, 867 active studies are being conducted to investigate the potential of Angeliq in treating Osteoporosis, Amenorrhea and Urogenital Atrophy.

Condition

Clinical Trials

Trial Phases

Hysterectomy

4 Actively Recruiting

Phase 3, Not Applicable

Breast Cancer

18 Actively Recruiting

Phase 2, Phase 1, Not Applicable

estradiol

0 Actively Recruiting

Birth Control

20 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Postmenopause

6 Actively Recruiting

Phase 2, Not Applicable

Metastatic Breast Cancer

1 Actively Recruiting

Phase 1, Phase 2

Osteoporosis, Postmenopausal

0 Actively Recruiting

Therapeutic procedure

0 Actively Recruiting

moderate to severe symptoms

0 Actively Recruiting

Balanitis Xerotica Obliterans

0 Actively Recruiting

Amenorrhea

1 Actively Recruiting

Phase 2

Osteoporosis

28 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Prostate Cancer

72 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1

Breast

0 Actively Recruiting

Urogenital atrophy

0 Actively Recruiting

Low Testosterone

4 Actively Recruiting

Phase 4, Phase 2, Phase 1

Vasomotor System

0 Actively Recruiting

Atrophic Vaginitis

2 Actively Recruiting

Not Applicable, Phase 4

Hot flashes

21 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Early Phase 1, Phase 3, Phase 1

Hormone Replacement Therapy

0 Actively Recruiting

Angeliq Reviews: What are patients saying about Angeliq?

5

Patient Review

6/13/2012

Angeliq for "Change of Life" Signs

I started using Angeliq a few years ago and saw incredible results. Not only did my hot flashes go away, but my skin, hair, and nails started growing! I had more energy and felt so much better overall. However, when I stopped taking it for just four months, everything took a turn for the worse. My hair fell out in chunks and I was incredibly depressed. As soon as I started taking it again though, I felt fantastic once more.

5

Patient Review

2/19/2015

Angeliq for Post-Menopausal Osteoporosis Prevention

This medication has been great for the past 2 years. It has helped with mood swings, hot flashes, and sleeping. However, my family doctor wants me to stop taking them as I am 52 and a smoker. He says the side effects are life threatening. But they have kept me sane.

5

Patient Review

12/8/2018

Angeliq for "Change of Life" Signs

I started using Angeliq when I was 55 and it's been amazing. My hot flashes stopped within hours of taking the first dose, and I've been sleeping through the night ever since. The only downside is the cost of the drug; it's way too expensive.

5

Patient Review

2/26/2015

Angeliq for "Change of Life" Signs

I used to suffer from hotflashes and night sweats for years before my OB/GYN prescribed this medication. I've been taking it for over five years now, and it works great! No hot flashes or night sweats at all since starting the medication, and no weight gain or moodiness either. I call it my miracle drug.

5

Patient Review

4/24/2016

Angeliq for "Change of Life" Signs

The first pill immediately stopped my hot flashes. I also found that I had more energy and could concentrate better than ever before. This treatment has literally given me a new lease on life.

5

Patient Review

11/26/2013

Angeliq for "Change of Life" Signs

The price is too high. $105.00 a month

4.3

Patient Review

4/28/2011

Angeliq for "Change of Life" Signs

This drug is excellent for reducing hot flashes, night sweats and moodiness. I've been taking it for two and a half years with only occasional bleeding every couple of weeks. It's also allowed me to sleep! The key is to take it at approximately the same time each day.

4.3

Patient Review

3/13/2013

Angeliq for "Change of Life" Signs

This drug has been great for controlling my anxiety, sleeplessness, and weight gain.

4.3

Patient Review

10/17/2022

Angeliq for "Change of Life" Signs

This treatment has been life-changing for me. After just two weeks, I stopped having hot flushes, felt less anxious, and actually started losing weight. I feel great every day and people have been complementing me nonstop.The only downside is that I sometimes get headaches and trouble sleeping, but even those are manageable compared to how bad things were before. I'll take this treatment for as long as possible!

4

Patient Review

4/20/2017

Angeliq for "Change of Life" Signs

I've been using this medication for about a month now, and it's done wonders for my hot flashes and night sweats. The only downside is that I've noticed some dark patches on my skin, but I'm hoping that's just a temporary side effect.

3.3

Patient Review

3/16/2011

Angeliq for "Change of Life" Signs

The hot flashes stopped immediately, but I started having more headaches and vaginal bleeding. I also lost interest in most things. Cutting my dose in half (by taking it every other day) helped, and I'm also starting to use a bioidentical menopause cream.

3.3

Patient Review

11/15/2012

Angeliq for "Change of Life" Signs

I've been taking this for two weeks and have observed both positive and negative changes. I stopped waking up at night, but then gained weight and became depressed. I would rather deal with menopause symptoms than be overweight and unhappy, so I'm going to stop taking the medication.

3.3

Patient Review

5/6/2016

Angeliq for "Change of Life" Signs

I experienced fewer hot flushes, but unfortunately my hair started falling out quite a bit. I had to discontinue use because of that side effect.

3

Patient Review

11/9/2021

Angeliq for "Change of Life" Signs

This medication has helped me a lot with my menopause symptoms, but I always experience breast pain and breakthrough bleeding/spotting after a couple of months. When I stop taking the medication, my symptoms come back. Not sure what to do at this point.

3

Patient Review

5/20/2013

Angeliq for "Change of Life" Signs

I've been using this treatment for three months now and I have noticed that the tenderness and pain in my left breast has gone down significantly.

2.7

Patient Review

3/27/2018

Angeliq for "Change of Life" Signs

I've unfortunately experienced weight gain, mood swings, and fatigue since starting this medication. I'm on my second month now and haven't felt any improvement.

Patient Q&A Section about angeliq

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Angeliq a good HRT?

"The average rating for Angeliq is 8.1 out of 10 from 38 total ratings for the treatment of Postmenopausal Symptoms. 76% of reviewers reported a positive experience, while 16% reported a negative experience."

Answered by AI

Does Angeliq make you gain weight?

"The text lists some of the possible side effects of a medication, which are: nausea, diarrhea, stomach pain, or fluid retention (swelling, rapid weight gain)."

Answered by AI

Does Angeliq cause hair loss?

"Angeliq (drospirenone / estradiol) may cause hair loss, although this is not a common side effect. If you start losing large amounts of hair or develop bald patches after starting this medication, you should let your health care provider know."

Answered by AI

What is Angeliq pills used for?

"This medication can help reduce menopause symptoms such as hot flashes, vaginal dryness, and itching."

Answered by AI

Clinical Trials for Angeliq

Image of Translational Physiology Laboratory within the Food Science Clinical Research Laboratory in Fort Collins, United States.

Mitoquinone for Postmenopausal Brain Health

18+
Female
Fort Collins, CO

The goal of this clinical trial is to learn if 3 months of taking the dietary supplement MitoQ \[a mitochondria-targeted antioxidant that targets to reduce mitochondrial reactive oxygen species (mitoROS)\] works to treat age- and menopause-related reductions in brain artery (cerebrovascular) function in postmenopausal women 60 years of age or older free of clinical disease. The main questions it aims to answer are: Does MitoQ improve cerebrovascular function in postmenopausal women? If so, does MitoQ improve cerebrovascular function by lowering mitoROS in these arteries? Researchers will compare MitoQ to a placebo (a look-alike substance that contains no drug) to see if MitoQ can improve cerebrovascular function by lowering mitoROS in arteries involved in brain health and function. Participants will: Take MitoQ (20 mg/day) or a placebo every day for 3 months Visit the research laboratory at baseline and then after 3 months for cerebrovascular testing; there is also a check-in visit at 6 weeks, which is the halfway point Keep track of symptoms and events during their treatment period to report to the study team

Waitlist Available
Dietary Supplement

Translational Physiology Laboratory within the Food Science Clinical Research Laboratory

Image of M D Anderson Cancer Center in Houston, United States.

Decision Support Tool for Prostate Cancer

18+
Male
Houston, TX

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

Waitlist Available
Has No Placebo

M D Anderson Cancer Center

Debanjan Pain

Have you considered Angeliq clinical trials?

We made a collection of clinical trials featuring Angeliq, we think they might fit your search criteria.
Go to Trials
Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Recruiting
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Angeliq clinical trials?

We made a collection of clinical trials featuring Angeliq, we think they might fit your search criteria.
Go to Trials
Image of University of Michigan Comprehensive Cancer Center in Ann Arbor, United States.

Self-Monitoring Platform for Cancer

18+
All Sexes
Ann Arbor, MI

This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.

Recruiting
Has No Placebo

University of Michigan Comprehensive Cancer Center

Yun Jiang

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Angeliq clinical trials?

We made a collection of clinical trials featuring Angeliq, we think they might fit your search criteria.
Go to Trials